...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>British Journal of Clinical Pharmacology >Cannabidiol for neurodegenerative disorders: Important new clinical applications for this phytocannabinoid?
【24h】

Cannabidiol for neurodegenerative disorders: Important new clinical applications for this phytocannabinoid?

机译：用于神经退行性疾病的大麻族：这种植物植物植物的重要新临床应用？

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Cannabidiol (CBD) is a phytocannabinoid with therapeutic properties for numerous disorders exerted through molecular mechanisms that are yet to be completely identified. CBD acts in some experimental models as an anti-inflammatory, anticonvulsant, anti-oxidant, anti-emetic, anxiolytic and antipsychotic agent, and is therefore a potential medicine for the treatment of neuroinflammation, epilepsy, oxidative injury, vomiting and nausea, anxiety and schizophrenia, respectively. The neuroprotective potential of CBD, based on the combination of its anti-inflammatory and anti-oxidant properties, is of particular interest and is presently under intense preclinical research in numerous neurodegenerative disorders. In fact, CBD combined with Δ9-tetrahydrocannabinol is already under clinical evaluation in patients with Huntington's disease to determine its potential as a disease-modifying therapy. The neuroprotective properties of CBD do not appear to be exerted by the activation of key targets within the endocannabinoid system for plant-derived cannabinoids like Δ9-tetrahydrocannabinol, i.e. CB1 and CB2 receptors, as CBD has negligible activity at these cannabinoid receptors, although certain activity at the CB2 receptor has been documented in specific pathological conditions (i.e. damage of immature brain). Within the endocannabinoid system, CBD has been shown to have an inhibitory effect on the inactivation of endocannabinoids (i.e. inhibition of FAAH enzyme), thereby enhancing the action of these endogenous molecules on cannabinoid receptors, which is also noted in certain pathological conditions. CBD acts not only through the endocannabinoid system, but also causes direct or indirect activation of metabotropic receptors for serotonin or adenosine, and can target nuclear receptors of the PPAR family and also ion channels.
机译：大麻（CBD）是一种植物植物植物，其具有治疗性质，用于通过尚未完全鉴定的分子机制施加的许多疾病。 CBD在一些实验模型中起作用，作为抗炎，抗惊厥，抗氧化剂，抗催吐剂，抗氧化和抗精神病药物，因此是治疗神经炎症，癫痫，氧化损伤，呕吐和恶心，焦虑和恶心的潜在药物精神分裂症分别。基于其抗炎和抗氧化剂性质的组合，CBD的神经保护潜力特别感兴趣，并且目前在许多神经变性障碍中存在强烈的临床前研究。事实上，CBD与Δ9-四氢甘油尼酚联合的患者患有亨廷顿疾病患者的临床评估，以确定其作为疾病改性治疗的潜力。 CBD的神经保护性能似乎不能通过在含Δ9-四氢尼醇（IE CB1和CB2受体）的植物衍生的大麻素，即CB1和CB2受体中的植物衍生的大麻素内的关键靶标的激活而施加，因为在这些大麻素受体中具有可忽略的活性，尽管某些活动在CB2受体中已经在特定的病理条件下记载（即未成熟的脑的损伤）。在Endocannabinoid系统中，已显示CBD对内突植物的灭活（即FAAH酶的抑制）具有抑制作用，从而提高了这些内源性分子对大麻素受体的作用，这也在某些病理条件下注目。 CBD不仅通过内胆蛋白系统作用，而且还会导致血清素或腺苷的代言菌受体的直接或间接激活，并且可以针对PPAR系列的核受体以及离子通道。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号